Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
August 22, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
June 28, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Neuronascent Announces the Expansion of its Board of Directors
April 12, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease
November 08, 2022 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged...
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
June 01, 2022 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
May 24, 2022 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage biopharmaceutical company discovering and developing neuron-generating therapies for rare developmental...
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
March 30, 2022 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain...
Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal
January 20, 2021 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, Md., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel...
Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease
May 07, 2019 05:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, Md., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has...
Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease
September 19, 2018 06:00 ET
|
Neuronascent, Inc.
CLARKSVILLE, Md., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute on Aging (NIA), part of...